PubMed Health⌕ Search

Biomedical subjects

S F Katircioğlu

Publications and source records attributed to S F Katircioğlu.

At least 19 recordsLinked to original sources
PubMed1999

Comparison of reoperation findings of the Carpentier-Edwards (standard) bioprosthesis and the St Jude bioimplant (formerly Liotta) in the mitral position.

Between 1986 and 1996, 50 patients with Carpentier-Edwards porcine bioprostheses and 211 with a St Jude bioprosthesis underwent reoperation because of structural valve deterioration. Structural valve deterioration was defined as an intrinsic abnormality of the prosthesis (leaflet disruption, calcification, leaflet thickening, etc.) that caused stenosis or regurgitation found on physical examination and echocardiography. Fifteen of the Carpentier-Edwards bioprosthesis group were male and 35 were female. Eighty-two of the St Jude group were male and 129 female. The mean age at reoperation was 33.88 +/- 10.31 years (range 19-70) for the Carpentier-Edwards group and 39.03 +/- 9.97 years (range 20-70) for the St Jude group. The average duration was 94.32 +/- 3.83 months for the Carpentier-Edwards group and 73.76 +/- 1.44 months for the St Jude group (P < 0.001). The mean aortic cross-clamp time was 67.4 min (minimum 32, maximum 210) for the St Jude group and 63.21 min (minimum 36, maximum 230) for the Carpentier-Edwards group. Reoperative hospital mortality was 10% (5/50) in the Carpentier-Edwards group and 7.1% (15/211) in the St Jude group (P > 0.05). Late failure modes of the bioprostheses were defined for the purposes of this study as calcification, stenosis and torn leaflets. Of the Carpentier-Edwards group, seven patients (14%) developed calcification, six patients (12%) developed stenosis and 13 patients (26%) developed leaflet tears. Of the St Jude group, the incidences were 22 patients (10%), 67 patients (31.8%) and 87 patients (41%), respectively. This study indicates that the Carpentier-Edwards bioprosthesis is more durable than the St Jude. The St Jude bioprosthesis tended to develop leaflet tears and linear calcification in female patients, and nodular calcification in male patients.

Adult↗
PubMed1999

Experimental inhibition of protamine cardiotoxicity by prostacyclin.

Twelve animals (26+/-5 kg) were subjected to the study. In this experimental study, the authors used prostacyclin to inhibit the toxic metabolite release during protamine administration. Animals were divided into two equal groups. Six animals received prostacyclin (the prostacyclin group), and the other six animals did not receive any additional treatment (the control group). All cardiac output and biochemical measurements were evaluated at baseline; before cardiopulmonary bypass; and at 5, 30, and 60 minutes after protamine administration. The measured cardiac index showed that the hearts treated with prostacyclin had satisfactory preservation of left ventricular function. Metabolic and biochemical data showed that the tumor necrosis factor level was raised significantly in the control group (20.75+/-2.2 in the control group and 13.75+/-2.5 pg/mL in the prostacyclin group). Also, E and P selectin levels were elevated in the control group, but this change was less marked in the prostacyclin group. In addition, the intracellular adhesion molecule-1 (ICAM-1) level was significantly higher in the control group than in the prostacyclin group (9.26+/-2.13 in the control group and 5.13+/-1.66 ng/mL in the prostacyclin group). The authors observed that prostacyclin inhibited the toxic mediator release during heparin reversal with protamine. This inhibition is one way of protecting the myocardium reserves from protamine cardiotoxicity.

Animals↗
PubMed1999

Coronary sinus retroperfusion during acute experimental coronary artery occlusion.

BACKGROUND: This study was planned to show the effect of retroperfusion and cardiopulmonary bypass on myocardial hemodynamic recovery. METHODS: Eighteen dogs entered this study. After, left anterior descending artery (LAD) was dissected and occluded, the animals were divided into three equal groups; Group I: retrograde coronary sinus perfusion, group II: cardiopulmonary bypass and retrograde coronary sinus perfusion, Group III: control group, left anterior descending artery occlusion only. RESULTS: In Group III, deterioration of the hemodynamic values progressed parallel with the degree of ischemic damage but in Group I, hemodynamic parameters were better because of the retrograde coronary sinus perfusion and minimally affected by the reperfusion. In Group II, at the end of the cardiopulmonary bypass minimal myocardial damage was observed. CONCLUSIONS: There is no statistical difference between Group I and II if we examine the data that was taken after reperfusion although myocardial performance was better in Group II.

Animals↗
PubMed1998

Iloprost added to the cardioplegic solutions improves myocardial performance.

A total of 12 mongrel dogs were divided into two equal groups. Six animals received IIoprost and the other 6 animals did not receive any additional treatment. In the Iloprost group, Iloprost was added to the cardioplegic solution (25 ng). Also, Iloprost was used (10 ng/kg/min.) 5 min. before and after cross-clamping. All cardiac output and biochemical measurements were evaluated before cross-clamp and 15 min., 1 h, and 4 h after cross-clamp. The measured dp/dt shows that the hearts treated with Iloprost preserved left ventricular function. Comparison of contractility indices between the groups revealed that contractile recovery was 59% in the control group and 71% in the Iloprost group (p < 0.05). Tumor necrosis factor (TNF) alpha level was significantly elevated in the control group (p < 0.001). Its level was 22.2 +/- 2.2 pg/mL in the control group and 13.8 +/- 1.0 pg/mL in the Iloprost group. E- and P-selectin levels were elevated in the control group (p < 0.001). ICAM-1 level was also elevated in the control group. ICAM-1 level was 17.7 +/- 1.8 ng/mL in the control group and 8.5 +/- 1.8 ng/mL in the Iloprost group. The Iloprost that was added to the cardioplegic solution and low dose administration during the pre- and post-ischemic period inhibits the toxic mediator release from endothelium-leukocyte interaction and reduces the severity of ischemia-reperfusion injury.

Adenosine Diphosphate↗
PubMed1998

Preservation of myocardial metabolism in acute coronary artery occlusions with retrograde coronary sinus perfusion and iloprost.

A total of 12 healthy mongrel dogs were subjected to the study. The left anterior descending artery was occluded. The occlusion was done for 15 min. At the end of this period, without removing the occlusion, the heart was retroperfused for 3 h. Then, occlusion was removed and reperfusion was supplied. Animals were divided into two equal groups. Six animals received iloprost and the other six control did not receive any additional treatment. In the iloprost group, the drug was administered into the coronary sinus. After 15 min following occlusion, iloprost was infused at a rate of 50 microg/min continuously. Cardiac output (CO), mean arterial pressure (MAP), mean pulmonary arterial pressure (MPAP), heart rate (HR), pulmonary capillary wedge pressure (PCWP), right atrium pressure (RAP), myocardial oxygen extraction (MOE) and myocardial lactate extraction (MLE) parameters were examined in the two groups, before and during retroperfusion and during the reperfusion (1-4 h). Iloprost retroperfusion (50 microg/min) was started at the fifteenth minute of occlusion and continued till the end of the observation period (3 h). The measured hemodynamic data showed that the hearts treated with iloprost had satisfactory preservation of cardiac function. At the end of the reperfusion period cardiac output was 1.5 +/- 0.06 L/min in the control and 1.7 +/- 0.04 L/min in the iloprost group (P < 0.05). At the end of the reperfusion period, tumor necrosis factor level was raised significantly in the control group (P < 0.05). Myocardial lactate release was also high in the control group (P < 0.05). CPK-MB release was low in the iloprost group (P < 0.05). We conclude that retrogradely administered iloprost reduced the risk of myocardial injury and it is probable that this drug effectively distributes to the area of myocardium at risk.

Animals↗
PubMed1998

Simplified retroperfusion system preserves the myocardial function during acute coronary artery occlusion.

It is known that coronary venous retroperfusion restores the blood flow to the ischemic myocardium, resulting in reduction of infarct size and improvement in left-ventricular pump function. In this study, we used an animal model to investigate the effects of a simplified coronary venous retroperfusion system on myocardial hemodynamics. Twenty dogs were entered in this study. All dogs underwent fifteen minutes occlusion of the left anterior descending artery. For the rest of the experiment the dogs were randomized into two groups: the control group (n = 10) underwent a further 2 hours left anterior descending artery occlusion, then clamps were released and the animals were observed for 6 hours. In the retroperfusion group (n = 10) a simple aortocoronary sinus connection was made and retrograde perfusion achieved with an outflow of 43 +/- 6 ml/min. Retrograde coronary sinus perfusion was maintained for three hours and then the dogs were observed for six hours. Tissue adenosine triphosphate levels were 6 +/- 3 mumol/g in the control group and 12 +/- 2 mumol/g in the retroperfusion group (p < 0.05) 6 hours after reperfusion. Creatine phosphokinase levels were 99 +/- 11 IU/L in the control group and 42 +/- 8 IU/L in the retroperfusion group 6 hours after reperfusion (p < 0.05). Cardiac index was 63 +/- 4 ml/kg/min in the control group and 79 +/- 2 ml/kg/min in the retroperfusion group 6 hours after retroperfusion (p < 0.05). Left-ventricular stroke-work index at a pulmonary capillary artery wedge pressure of 20 mmHg was 0.54 +/- 0.06 g.m/kg in the retroperfusion group and 0.29 +/- 0.03 g.m/kg in the control group 6 hours after reperfusion (p < 0.05). It is concluded that myocardial hemodynamic and biochemical function can be preserved by simplified coronary sinus retroperfusion.

Animals↗
PubMed1996

Spinal cord protection with the use of prostacyclin during aortic occlusion.

This study was planned to investigate if prostacyclin (PGI2) would reduce spinal cord injury following aortic occlusion. Twelve dogs underwent 90 min of aortic occlusion. Six dogs received PGI2 and the remaining animals did not. PGI2 was administered at a dose of 25 ng/kg/min during occlusion of the aorta. There were five paraplegic animals in the control group and one in the PGI2 group 72 hr after aortic occlusion. Neurological recovery was better in the PGI2 group than in the control group (P < 0.05). Malondialdehyde level was 3.55 +/- 0.58 nmole/ml in the PGI2 group and 6.35 +/- 1.27 nmole/ml in the control group 60 min after aortic cross-clamp removal (P < 0.05). At the same time interval, protein thiol groups were 629 +/- 50 micromole/L in the PGI2 group and 376 +/- 69 micromole/L in the control group (P < 0.05). Distal arterial pressure and central venous pressure were 15 +/- 4 and 12 +/- 3 mm Hg in the control group and 33 +/- 5 and 7 +/- 1.6 mm Hg in the PGI2 group, respectively (P < 0.05). In this study exogenously administered PGI2 protected the spinal cord from the hazardous effects of aortic occlusion lasting 90 min.

Animals↗
PubMed1996

Enoximone usage for experimental spinal cord protection during aortic cross-clamping.

Spinal cord preservation during aortic cross-clamping is of vital importance. Maintenance of spinal cord blood supply is one of the key points for spinal cord preservation. In this study enoximone was selected as an agent to reduce the risk of spinal cord injury because of its inotropic and vasodilator actions. Ten dogs underwent sixty minutes aortic occlusion. Five animals received enoximone and the others did not (the control group). Enoximone dosage was 10 microgram/kg/min. Four dogs in the control group suffered paraplegia. There were no paraplegic events in the enoximone group. Cerebrospinal fluid pressure was 17 +/- 3 mmHg in the control group, 15 +/- 4 mmHg in the enoxirmone group. Distal aortic pressure was 15 +/- 4 mmHg in the control group, 47 +/- 6 in the enoximone group (p < 0.001). In this study we conclude that enoximone is an effective agent to reduce the risk of spinal cord injury.

Animals↗
PubMed1995

Beneficial effects of prostacyclin treatment on reperfusion of the myocardium.

A total of 20 patients with coronary artery disease were studied in order to assess the benefits of prostacyclin administration on reperfusion of the ischaemic myocardium after cardiopulmonary bypass. Ten received prostacyclin (25 ng/kg per min) while ten were untreated controls. There was no difference between groups with regard to age, preoperative ejection fraction and aortic cross-clamping times. There were no in-hospital deaths in either group. The administration of prostacyclin significantly altered the metabolic side effects of reperfusion followed by hypothermic cardioplegic arrest. Myocardial oxygen consumption after cardiopulmonary bypass was significantly higher in the prostacyclin-treated group than in controls (18.5 ml versus 13 ml; P < 0.01). Prostacyclin treatment significantly reduced the leucocyte activity: leukotriene B4 concentrations were 58 pmol/l in prostacyclin-treated patients compared with 93 pmol/l in controls (P < 0.01). Such recovery of metabolic status during reperfusion resulted in better haemodynamic function in patients receiving prostacyclin.

Coronary Artery Bypass↗
PubMed1995

Risk factors of reoperations for prosthetic heart valve dysfunction in the ten years 1984-1993.

From January 1984 to December 1993 a total of 154 patients (89 men and 85 women) required 160 reoperations for prosthetic heart valve dysfunction. Four patients required a second, two patients a third reoperation. Age was (mean +/- SD [range]) 38.8 +/- 10.2 (17 to 64) years. The primary operation was mitral valve replacement in 105 patients, aortic valve replacement in 20, and both aortic and mitral valve replacement in 29. The time interval between initial valve replacement and reoperation was 66.4 +/- 40 (3 to 288) months for the mechanical prostheses and 68.7 +/- 32 (24 to 140) months for bioprostheses; the difference was not statistically significant. Primary tissue failure was the most common cause of the reoperation for bioprostheses and valve thrombosis for mechanical prostheses. The hospital mortality rate was significantly higher in the replacement of mechanical prostheses (14/58 = 24.1% vs. 7/102 = 6.8%, p = 0.004). Low preoperative functional capacity and valve thrombosis were linked to higher mortality rates. It is discussed that monoleaflet mechanical valves yielded the highest operative mortality and that, excluding these, the risk of mortality in prosthetic valve reoperations today does not differ much from that in primary valve replacements.

Adult↗
PubMed1995

Cardiomyoplasty.

Explore the source record for details and available documents.

Cardiomyoplasty↗
PubMed1994

Coronary sinus retroperfusion combined with intraaortic balloon pumping to perfuse the acutely ischemic myocardium.

This study was planned to show the effect of retroperfusion and intraaortic balloon pumping (IABP) on myocardial hemodynamic recovery. Twelve dogs entered this study. Half of them received IABP and coronary sinus retroperfusion (CSPR) combination (Group II) and the remaining received IABP alone (Group I). Left anterior descending artery was occluded for a period of three hours. 15 minutes after occlusion IABP and IABP + CSRP were initiated. The average cardiac output was 1.41 +/- 0.18 L/min in the group I and 1.72 +/- 0.24 L/min in the group II (p < 0.03) after 3 hours of occlusion. Mean arterial pressure was 82.1 +/- 4.8 mmHg in the group I and 89.7 +/- 2.6 mmHg in the group II (p < 0.03). On the basis of this study it was concluded that CSRP + IABP could be an alternative treatment to IABP alone during the acutely developing ischemia.

Acute Disease↗
PubMed1993

Warm blood cardioplegia: ultrastructural and hemodynamic study.

Forty patients with coronary artery disease were included in this study. Half of them received cold crystalloid and cold blood cardioplegia (group 1), and half received normothermic blood cardioplegia (group 2). In group 1, left ventricular stroke work index was 24 +/- 3 g.m/m2 1 hour after the operation, 29 +/- 8 g.m/m2 12 hours after the operation, and 33 +/- 6 g.m/m2 24 hours after the operation. In group 2, left ventricular stroke work index was 37 +/- 4 g.m/m2 1 hour after the operation, 37 +/- 4 g.m/m2 12 hours after the operation, and 44 +/- 7 g.m/m2 24 hours after the operation. Myocardial oxygen extraction 20 minutes after the termination of cardiopulmonary bypass was 0.28 +/- 0.03 in group 1 and 0.44 +/- 0.08 in group 2. Myocardial lactate extraction at the same time was -0.09 +/- 0.02 in patients receiving cold blood cardioplegia and 0.17 +/- 0.07 in patients receiving normothermic blood cardioplegia. Electron microscopic study revealed no calcium accumulation in the mitochondria in group 2 patients, whereas calcium accumulation was present in the other group.

Aged↗